By Eric Sagonowsky
The pharma industry’s massive pandemic response may have yielded another winner, as Eli Lilly’s Olumiant—combined with Gilead Sciences' remdesivir—improved recovery time in patients hospitalized with COVID-19. And with that data, Lilly's plotting its course for an FDA emergency authorization.
read more
By Tina Reed
In a new Medscape report on the impact of COVID-19 on doctors, nearly a quarter of U.S. doctors said they'd lost 50% or more of their income.
read more
By Kyle Blankenship
As new COVID-19 infections and deaths continue to march downward in the U.S., companies are having to make a difficult choice: Stay at home or back to business as usual? For drugmaker AbbVie, this week marks a return to normal for part of its workforce—but some employees have their reservations.
read more
By Kyle Blankenship
The biggest drugmakers in the hunt for a COVID-19 vaccine have been racing to lock up national supply deals for months in anticipation of global demand for a winner. Even the lesser-known contestants are selling their wares around the world, though—and the U.K. appears to be buying.
read more
By Eric Sagonowsky, Angus Liu, Kyle Blankenship, Conor Hale, Fraiser Kansteiner
The U.K.'s Recovery Trial will test Regeneron's antibody cocktail in hospitalized COVID-19 patients. Two former FDA chiefs touted the benefits of an emergency nod for a vaccine. Vaxart snared approval to run a phase 1 trial of its oral vaccine hopeful. And AbbVie ordered staffers back to work despite COVID-19 fears.
read more
By Healthcare Staff
Follow along with the latest COVID-19 news straight from the Fierce Healthcare team.
read more
By Paige Minemyer
COVID-19 is proving the value of Medicare Advantage's holistic approach to care, Humana CEO Bruce Broussard said Monday.
read more
